Market Newsdesk

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, today announced that it will participate in the following investor conferences in September.

H.C. Wainwright 25

^th

Annual Global Investment Conference

Date: September 11-13, 2023
Location: Lotte New York Palace Hotel, New York, NY
Date and Time of Presentation: Available September 11, 2023, at 7:00 a.m. ET
Format: Corporate Presentation and 1×1 meetings
Webcast Link: https://journey.ct.events/view/3eb50cf4-1561-4363-8e78-ac2c56092fb6

Cantor Fitzgerald Annual Global Healthcare Conference

Dates: September 26-28, 2023
Location: InterContinental Barclay Hotel, New York, NY
Date and Time of Panel Presentation: September 26, 2023, at 11:35 a.m. ET
Format: Panel Presentation and 1×1 meetings

A webcast of the presentations, if available, will be available on the “Events” section of the Clene website.

About Clene


Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.

Contacts:

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two presentations at the upcoming World Molecular Imaging Congress (WMIC) 2023, hosted by the World Molecular Imaging Society (WMIS). The conference is being held in Prague, Czech Republic, from September 5-9, 2023.

“We are pleased with our team’s progress in pioneering the development of promising image-guided, lead-based, alpha particle therapies.” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics. “Our team continues to deepen our pipeline with exceptional data from our novel radioligand, [^203/212Pb]PSC-PEG3-Adma, for image-guided pre-targeted alpha particle therapy; and our preclinical data for our lead-based alpha particle therapy, [²¹²Pb]VMT-α-NET, continues to support ongoing clinical studies in India and our planned U.S.-based studies. We expect to provide preliminary clinical results this quarter. “

“We are excited to present some of our latest data collected in collaboration with our partner and lead author Dr. Dongyoul Lee PhD (Assistant Professor, Korea Military Academy) highlighting [²¹²Pb]VMT-α-NET and its efficacy in the treatment of neuroendocrine tumors and the image-guided approach using imaging surrogate [²⁰³Pb]VMT-α-NET. We demonstrated the significant therapeutic benefit of [²¹²Pb]VMT-α-NET in a mouse model and the potential for high probability of complete response.” commented Michael K. Schultz, Ph.D., Chief Scientific Officer at Perspective Therapeutics. “Furthermore, we are excited to be collaborating with our partner Jacob Houghton PhD (Assistant Professor, Radiology at Stony Brook University) to showcase a novel and game-changing guest/host platform for effective in vivo image-guided pre-targeted alpha particle therapy. Radioligand [²⁰³Pb]PSC-PEG3-Adma demonstrated extended lag times, impressive tumor-to-tissue ratios and with our ongoing efforts using a PSC chelator, we have the potential to further reduce radiation toxicity during therapy using the elementally identical therapeutic ligand [²⁰³Pb]PSC-PEG3-Adma as a guide.”

Presentation One:

Title: Targeted Alpha Therapy for Neuroendocrine Tumors: Therapeutic Efficacy and Dosimetry Analysis of [²¹²Pb]VMT-α-NET in Preclinical Models

Summary: This presentation highlights the potential for lead-based targeted alpha particle therapy, using [²¹²Pb]VMT-α-NET, in effectively treating neuroendocrine tumors. In a tumor xenograft mouse model, treatment with fractionated dosing of ²¹²Pb-VMT-α-NET resulted in 70% complete response and an 80% survival rate at 120 days.

Abstract ID: 131
Session: Radiotheranostics: Probe Development and Beyond, Oncology
Presenter: Michael K. Schultz, Ph.D., chief scientific officer, Perspective Therapeutics on behalf of Major Dr. Dongyoul Lee PhD, Assistant Professor, Korean Military Academy, Seoul, South Korea.
Date and Time: Thursday, September 7, 2023, 11:00 a.m. CEST 
Location: Panorama Hall

Presentation
Two
:

Title: Cucurbit[7]uril-adamantane host:guest pretargeting with ²⁰³Pb-labeled radioligands in xenograft models

Summary: In this presentation, favorable radiochemical and in vivo characteristics of novel radioligand [²⁰³Pb]PSC-PEG3-Adma is described for image-guided alpha-particle therapy. Synthesized with exceptional yield and purity, the radioligand demonstrated rapid and preferential tumor accumulation and lag time longer than other radioligands in development.

Session: Opening Reception and Poster Session 1: Preclinical Imaging
Presenter:  Amritjyot Kaur, Ph.D.
Date and Time: Wednesday, September 6, 2023, 5:30 p.m. – 7:30 p.m. CEST 
Location: Exhibit Hall

Details about the presentations can be found on the WMIC website (wmis.org/wmic-2023-about/). Additionally, a copy of the abstracts will be available on the Publications page of the Perspective Therapeutics website following the conference. 

About Perspective Therapeutics, Inc. 

Perspective Therapeutics, Inc., is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope Lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. 

The Company’s melanoma (VMT-01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. 

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement 

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s clinical development plans and the expected timing thereof; the expected timing for availability and release of data; the potential functionality, capabilities, and benefits of the Company’s product candidates; the Company’s expectations, beliefs, intentions, and strategies regarding the future; the Company’s intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the potential that regulatory authorities may not grant or may delay approval for the Company’s product candidates; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; pre-clinical and early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of regulatory authorities may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company’s ability to obtain and maintain regulatory approval for the Company’s product candidates; delays, interruptions or failures in the manufacture and supply of the Company’s product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its clinical development programs; the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of its product candidates; the ability of the Company to manage growth and successfully integrate its businesses; the Company’s ability to maintain its key employees; sufficient training and use of the Company’s products and product candidates; the market acceptance and recognition of the Company’s products and product candidates; the Company’s ability to maintain and enforce its intellectual property rights; the Company’s ability to maintain its therapeutic isotope supply agreement with the Department of Energy; the Company’s ability to continue to comply with the procedures and regulatory requirements mandated by the FDA for additional trials, Phase 1 and 2 approvals, Fast Track approvals, and 510(k) approval and reimbursement codes; and any changes in applicable laws and regulations. Other factors that may cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s most recent Transition Report on Form 10-KT and the Company’s most recent Quarterly Report on Form 10-Q, each filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov.

Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law. 

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) — ExlService Holdings, Inc. (“EXL”) (NASDAQ: EXLS), a leading data analytics and digital operations and solutions company, today announced that Rohit Kapoor, vice chairman and chief executive officer, will participate in the 2023 Citi Global Technology Conference in New York. A company presentation and simultaneous webcast will take place on Wednesday, Sept. 6.

A link to the webcast is available in the Investor Relations section of EXL’s website at ir.exlservice.com. A replay will be available for approximately 90 days on the company’s website.

About ExlService Holdings, Inc.

EXL (NASDAQ: EXLS) is a leading data analytics and digital operations and solutions company that partners with clients to improve business outcomes and unlock growth. By bringing together deep domain expertise with robust data, powerful analytics, cloud, artificial intelligence and machine learning, we create agile, scalable solutions and execute complex operations for the world’s leading corporations in industries including insurance, healthcare, banking and financial services, media, and retail, among others. Focused on driving faster decision-making and transforming operating models, EXL was founded on the core values of innovation, collaboration, excellence, integrity and respect. Headquartered in New York, our team is over 48,000 strong, with more than 50 offices spanning six continents. For more information, visit www.exlservice.com.

Contact:
John Kristoff
Vice President, Investor Relations
+1 212 209 4613
[email protected]

RANCHO SANTA MARGARITA, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) — Melissa, a leading provider of global data quality, identity verification, and address management solutions, today announced its support of healthcare practice management providers in meeting compliance with Project US@, a federal data initiative to create a unified, industrywide specification for representing patient addresses.

“Good data always matters, but in healthcare it has the power to improve the standard of care,” said Bud Walker, Vice President, Enterprise Sales and Strategy, Melissa. “With Project US@, the federal government acknowledges that standardized patient address data is foundational to processes that advance population health as well as optimize practice management.”

Project US@ was established by the Office of the National Coordinator (ONC) for Health Information Technology to create standards for patient address information. The initiative leverages the expertise of the USPS®, the nation’s authority on addresses and related data quality standards. Project US@’s primary goal is to improve patient matching across healthcare’s broad spectrum of clinical and administrative processes, enhancing the performance of patient matching algorithms through improved address quality.

Determining if records correctly refer to a specific patient is critical to patient safety, whether the record is held within a single healthcare organization or across different healthcare organizations. Greater accuracy also improves administrative processes and the interoperability of patient records. By adopting Project US@, practice management platforms anticipate a reduced burden associated with developing and continuously working to improve patient query and matching efficiency, errors in de-duplicating patient records and billing, and other challenges.

“Address verification has been integral to our offering since day one. By tapping into Melissa’s data quality tools, our platform ensures comprehensive attention to clean data,” said Tom Langan, President and Chief Commercial Officer of Veradigm Inc. (NASDAQ:MDRX), a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. “Today, our Veradigm Practice Management users have access to a Project US@-compliant platform that recognizes address standardization and verification is important not just for practice management but for all phases and levels of healthcare operations.”

Melissa’s Address Object and Personator tools are in compliance with the Project US@ Technical Specification for Patient Addresses Domestic and Military, Version 1.0. These products validate address information at the point of entry in patient registration and standardize address information according to USPS® guidelines. With Melissa’s support, practice management platforms can verify, standardize, and correct postal addresses with a USPS® CASS & Canada Post SERP Certified address engine, updating missing or incorrect information in real time. Duplicates are matched and eliminated, meeting a critical goal of Project US@. This includes all-in-one verification and standardization capabilities that leverage a comprehensive dataset of billions of consumer records to validate that phone numbers, email addresses, social security numbers (SSN), and full names are valid and associated with a particular individual.

Melissa’s Project US@ support is an extension of its long list of cloud, industry, and postal compliance certifications, including HIPAA, HITECH, and HITRUST for Protected Health Information (PHI). These certifications underscore Melissa’s commitment to security and quality, and its deep experience in protecting and managing personally identifiable information (PII) and financial data.

Click here for more insight on Melissa’s Project US@-compliant tools and services. To connect with members of Melissa’s global intelligence team, visit www.Melissa.com or call 1-800-MELISSA.

About Melissa

Since 1985, Melissa has specialized in global intelligence solutions to help organizations unlock accurate data for a more compelling customer view. More than 10,000 clients worldwide in arenas such as retail, education, healthcare, insurance, finance, and government, rely on Melissa for full spectrum data quality and ID verification software, including data matching, validation, and enhancement services to gain critical insight and drive meaningful customer relationships. For more information or free product trials, visit www.Melissa.com or call 1-800-MELISSA (635-4772).

Media contacts


Greg Brown
Vice President, Global Marketing, Melissa
[email protected]
+1-800-635-4772 x1130

MPowered PR for Melissa
[email protected]
+1-877-794-6777

HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25^th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

Dr. Vera will provide an overview of Marker’s advancements and clinical development programs on Wednesday, September 13, 2023, at 8:30 a.m. EDT. Of note, Marker believes its therapies are superior to CAR T cells because Marker’s therapies use cancer killing T cells that are not genetically engineered and have more ways to recognize cancer cells than what is possible with current CAR T cell therapies.

During the conference, Dr. Vera and members of Marker will conduct one-on-one meetings with registered investors.

Details of the presentation are as follows:

The presentation will be available for replay starting September 14, 2023 on the Investors & Media section of Marker’s website.

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The cell therapy technology Marker has in place is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e., tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer the T cells, Marker believes that its product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Forward-Looking Statements

This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning Marker’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct and success of our clinical trials of our product candidates. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in Marker’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. Marker assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.

Contacts


TIBEREND STRATEGIC ADVISORS, INC.


Investors
Daniel Kontoh-Boateng
(862) 213-1398
[email protected]

Media
Casey McDonald
(646) 577-8520
[email protected]

PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), announced that Lisa Ricciardi, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conference in September 2023. In addition, she will be moderating a panel on pipeline prioritization strategies at the Longwood Healthcare Leaders Fall Conference, a brainstorming forum of pharmaceutical, healthcare and investment leaders focused on accelerating the translation of discoveries into medicines.

Presentation Details:

H.C. Wainwright Annual Global Investment Conference

Dates: September 11-13, 2023
Presentation Day/Time: September 13 at 4:00 pm
Location: Kennedy II, Lotte New York Palace, New York
Live webcast will be available on the events and presentations section of Cognition’s IR site during the event

Longwood Healthcare Leaders Fall Conference

Dates: September 18-19, 2023
Presentation Day/Time: September 19 at 4:10pm
Location: Harvard Medical School, Boston

Cantor Fitzgerald Global Healthcare Conference

Dates: September 26-28, 2023
Presentation Day/Time: September 26 at 9:20 am
Location: Intercontinental Barclay Hotel, New York
Live webcast will be available on the events and presentations section of Cognition’s IR site during the event

About Cognition Therapeutics:

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, and cash runway, involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies being predictive of the results of clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the ongoing COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of our annual and quarterly reports filed the Securities Exchange Commission. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact Information:
Cognition Therapeutics, Inc.
[email protected]

Casey McDonald (media)
Tiberend Strategic Advisors, Inc.
[email protected]    

Daniel Kontoh-Boateng (investors)
Tiberend Strategic Advisors, Inc.
[email protected]